In Celexir’s framework, NAD+ is positioned as a cornerstone coenzyme for healthy aging—supporting mitochondrial energy, genome maintenance, and neurologic resilience. Clinically, providers use it in longevity, anti-fatigue, and neuroprotection programs to help restore cellular energy handling and DNA repair capacity, with ready-to-use formats and full GMP documentation to keep protocols consistent.
Biologically, NAD+ sits at the hub of redox reactions and activates sirtuins while fueling PARP-mediated DNA repair, mechanisms tied to stress resistance and cellular maintenance across tissues. A large body of scholarship shows age-associated NAD+ decline driven by increased consumption (e.g., PARPs/CD38) and impaired biosynthesis, linking low NAD+ to metabolic dysfunction, impaired DNA repair, and senescence signaling—key hallmarks of aging.
Human evidence is strongest for precursor strategies (e.g., nicotinamide riboside, NMN) that raise NAD+ and modulate downstream biomarkers: dose-dependent NAD+ increases have been shown in blood and skeletal muscle; small trials report changes in neuronal EV biomarkers and mixed effects on metabolic endpoints. These signals support the rationale for NAD+-targeted longevity care, while highlighting the need for larger, longer RCTs powered for hard outcomes.
Celexir delivery & diligence: Catalog options include injectable pen / nasal spray / IV-grade (by request) with typical protocol equivalents of 50–250 mg, >98% purity, and 2–8 °C storage, supplied with CoA/MSDS. Note that NAD+ therapies are not FDA-approved for anti-aging indications, and the FDA has cautioned about adverse events from injectable NAD+ associated with endotoxin contamination—so use quality-verified lots, informed consent, and monitor outcomes.